A new drug from Roche Holding AG helped shrink the tumors of 25 percent of women with HER2-positive breast cancer, according to data from a mid-stage clinical trial, the Swiss company said on Thursday.
The treatment, trastuzumab-DM1, is a combination of Roche's Herceptin and a chemotherapy agent.
About 35 percent of patients 112 in the trial either saw their tumors shrink, or their disease stabilized for at least six months, Roche said.
© 2009 Reuters. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters.
|
